ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,304.80
0.00%
Dow Jones
40,421.36
0.33%
Brent Oil
81.725
0.26%
Bitcoin
66,508.11
-1.63%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Astria Therapeutics Inc (ATXS) Quote

Astria Therapeutics Inc

Astria Therapeutics Inc (ATXS)

NASDAQ
11.77
0.00
(0.00%)
Closed July 23 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
11.77
Bid
11.48
Ask
11.96
Volume
-
0.00 Day's Range 0.00
4.26 52 Week Range 16.90
Market Cap
646.327M
Previous Close
11.77
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
533,825
Shares Outstanding
54,913,061
Dividend Yield
-
PE Ratio
-6.43
Earnings Per Share (EPS)
-1.33
Revenue
-
Net Profit
-72.89M

About Astria Therapeutics Inc

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for... Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.astriatx.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Astria Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATXS. The last closing price for Astria Therapeutics was $11.77. Over the last year, Astria Therapeutics shares have traded in a share price range of $ 4.26 to $ 16.90.

Astria Therapeutics currently has 54,913,061 shares outstanding. The market capitalization of Astria Therapeutics is $646.33 million. Astria Therapeutics has a price to earnings ratio (PE ratio) of -6.43.

ATXS Latest News

More News

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase...

July 02 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

June 06 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 06 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 06 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 06 2024
Edgar (US Regulatory)

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase...

June 04 2024
Business Wire

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne...

May 30 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.22-1.8348623853211.9912.2510.8834483811.34675823CS
42.6228.63387978149.1512.258.8248580210.16311728CS
122.6228.63387978149.1512.258.5855338259.57539527CS
262.8231.50837988838.9516.97.9480888612.17037061CS
522.121.71664943129.6716.94.2657048510.56414747CS
1563.2437.98358733888.5316.92.3628825110.32294605CS
2603.2437.98358733888.5316.92.3628825110.32294605CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.162
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.91
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.51
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.35
(0.00%)
0
AACGATA Creativity Global
$ 0.65
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.162
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.91
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.51
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.35
(0.00%)
0
AACGATA Creativity Global
$ 0.65
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.162
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.91
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.51
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.35
(0.00%)
0
AACGATA Creativity Global
$ 0.65
(0.00%)
0

ATXS Discussion

View Posts
Monksdream Monksdream 3 weeks ago
ATXS under $10
👍️0
Monksdream Monksdream 3 months ago
ATXS under $10
👍️0
GreenStockEVs GreenStockEVs 1 year ago
NEWS OUT - Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com.
👍️0

Your Recent History

NASDAQ
ATXS
Astria Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved